Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab SC vs IV with RVd in Newly Diagnosed Multiple Myeloma
NCT05804032Phase 3Completed
- Start
- Apr 2023
- Primary completion
- Jan 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of isatuximab in multiple myeloma (MM) (2 arms). Primary endpoint: Very Good Partial Response or better at 18 weeks. Started Apr 2023; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05804032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804032.